CUPERTINO, Calif., Aug 24, 2001 /PRNewswire/ — In conjunction with
DURECT Corporation’s (Nasdaq: DRRX) press release regarding Chronogesic(TM)
Phase II clinical trial data, you are invited to listen to its conference call
that will be broadcast live over the Internet on Wednesday, September 5, 2001 at
8:30 a.m. EDT with Jim Brown, President and Chief Executive Officer, Felix
Theeuwes, Chairman and Chief Scientific Officer and Dennis Fisher, Vice
President of Medical Affairs and Medical Director.
What: DURECT Corporation Chronogesic Phase II clinical trial data
conference call
When: Wednesday, September 5, 2001, 8:30 a.m. EDT
Where: http://www.www.durect.com/wt/frame.php?page_name=investor
How: Live over the Internet -- Simply log on to the Web
at the address listed above or access through DURECT's Website.
DURECT Corporation is pioneering the development and commercialization of
pharmaceutical systems that will deliver the right drug to the right site in the
right amount at the right time. DURECT’s pharmaceutical systems combine
technology innovations from the medical device and drug delivery industries with
proprietary pharmaceutical and biotechnology drug formulations. These
capabilities can enable new drug therapies or optimize existing therapies based
on a broad range of compounds, including small molecule pharmaceuticals as well
as biotechnology molecules such as proteins, peptides and genes. Founded in
1998, the Company is headquartered in Cupertino, CA. The Company’s World Wide
Web site can be accessed at http://www.www.durect.com. To join DURECT’s email alert
service, please register by selecting “Email Alerts” on the main Investor
Relations web page at http://www.www.durect.com
If you are unable to participate during the live webcast, the call will be
archived at: http://www.www.durect.com/wt/frame.php?page_name=investor
Minimum Requirements to listen to broadcast: The RealPlayer software,
downloadable free from http://www.real.com/products/player/index.html, and at
least a 14.4Kbps connection to the Internet. If you experience problems
listening to the broadcast, send an email to webmaster@vdat.com.
The statements in this press release regarding DURECT’s products in development,
product development plans, or expected product benefits, are forward-looking
statements involving risks and uncertainties that could cause actual results to
differ materially from those in such forward-looking statements. Potential risks
and uncertainties include, but are not limited to, DURECT’s ability to develop,
manufacture and commercialize its products, successfully complete clinical
trials, obtain product and manufacturing approvals from regulatory agencies, and
validate and qualify a manufacturing facility, as well as marketplace acceptance
of DURECT’s products. Further information regarding these and other risks is
included in the company’s S-1 registration statement, filed with the SEC on
September 22, 2000, 424(b) prospectus filed with the SEC on September 28, 2000,
Quarterly Report on Form 10Q for the quarter ended June 30, 2001 filed with the
SEC on August 14, 2001 and Annual Report on Form 10K for the fiscal year ended
December 31, 2000 filed with the SEC on March 30, 2001.
SOURCE DURECT Corporation
CONTACT: Schond L. Greenway at +1-408-777-1417 for DURECT Corporation
/Audio: http://www.www.durect.com/wt/frame.php?page_name=investor